Pub Date : 2025-02-12DOI: 10.1080/02770903.2025.2463979
Laurence E Ruane, Joo Koh, Malcolm Baxter, Paul Finlay, Kathy Low, Rachael Hillman, Lucy Ruane, Garun Hamilton, Paul Leong, Philip Bardin
Objective: Vocal cord dysfunction/inducible laryngeal obstruction (VCD/ILO) commonly co-exists with asthma and can start after viral infections. In this setting evidence suggests that dysfunctional breathing may induce the disorder but this possibility has not been researched. We therefore postulated that dysfunctional breathing can induce VCD/ILO, more so in people with asthma and after viral infections.
Methods: Eight healthy control subjects, 16 people with asthma and eight people who had recent COVID-19 infection (three with asthma) were recruited. Video-recorded laryngoscopy was performed at tidal breathing and during controlled hyperventilation (used as a proxy for dysfunctional breathing). VCD/ILO was diagnosed by laryngoscopy using accepted criteria and correlated with study cohorts, clinical attributes, asthma severity and spirometry.
Results: Overall, 32 subjects were studied. Hyperventilation was verified in all subjects. None of the healthy control group or people with mild asthma developed VCD/ILO during or after hyperventilation but one person with moderate/severe asthma had clear evidence of VCD/ILO. In contrast, in people who had COVID-19 infection, hyperventilation induced VCD/ILO in 3/8 people (38%).
Conclusion: These proof-of-concept studies suggest that hyperventilation can provoke VCD/ILO in asthma and after a recent viral infection. How and why VCD/ILO develops is not known and these preliminary findings should prompt further studies of links between dysfunctional breathing, asthma, and viral infections.
{"title":"Vocal cord dysfunction/inducible laryngeal obstruction induced by hyperventilation in healthy individuals, people with asthma, and following coronavirus infection.","authors":"Laurence E Ruane, Joo Koh, Malcolm Baxter, Paul Finlay, Kathy Low, Rachael Hillman, Lucy Ruane, Garun Hamilton, Paul Leong, Philip Bardin","doi":"10.1080/02770903.2025.2463979","DOIUrl":"10.1080/02770903.2025.2463979","url":null,"abstract":"<p><strong>Objective: </strong>Vocal cord dysfunction/inducible laryngeal obstruction (VCD/ILO) commonly co-exists with asthma and can start after viral infections. In this setting evidence suggests that dysfunctional breathing may induce the disorder but this possibility has not been researched. We therefore postulated that dysfunctional breathing can induce VCD/ILO, more so in people with asthma and after viral infections.</p><p><strong>Methods: </strong>Eight healthy control subjects, 16 people with asthma and eight people who had recent COVID-19 infection (three with asthma) were recruited. Video-recorded laryngoscopy was performed at tidal breathing and during controlled hyperventilation (used as a proxy for dysfunctional breathing). VCD/ILO was diagnosed by laryngoscopy using accepted criteria and correlated with study cohorts, clinical attributes, asthma severity and spirometry.</p><p><strong>Results: </strong>Overall, 32 subjects were studied. Hyperventilation was verified in all subjects. None of the healthy control group or people with mild asthma developed VCD/ILO during or after hyperventilation but one person with moderate/severe asthma had clear evidence of VCD/ILO. In contrast, in people who had COVID-19 infection, hyperventilation induced VCD/ILO in 3/8 people (38%).</p><p><strong>Conclusion: </strong>These proof-of-concept studies suggest that hyperventilation can provoke VCD/ILO in asthma and after a recent viral infection. How and why VCD/ILO develops is not known and these preliminary findings should prompt further studies of links between dysfunctional breathing, asthma, and viral infections.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-07DOI: 10.1080/02770903.2025.2451690
Pca Almeida, Ev Ponte, R Stelmach, Tw Harrison, N Scichilone, A Souza-Machado, Aa Cruz
Background: Inhaled corticosteroids (ICS) are the preferred treatment for asthma. They improve symptoms and reduce exacerbations and deaths, but their long-term impact on lung function loss remains unclear, especially after delayed treatment. We aimed to characterize the lung function trajectories in subjects with previously untreated severe asthma. The secondary aim was to identify predictors of FEV1 decline, and future exacerbations.
Methods: This is a post-hoc analysis that followed 184 subjects with asthma for 10 years after a delayed start of regular maintenance ICS treatment. Absolute lung function variation was calculated using two different baselines: (i) FEV1 after one year of regular treatment (V1) and (ii) best FEV1 observed any time before the final visit.
Results: Most individuals were female (84%) over 50 years old and had early-onset asthma with a median of 30 years without regular ICS treatment. Ninety-nine (54%) had an FEV1 decline above 25ml/year, using strategy (i). Those subjects were younger, had shorter duration of asthma, and had better lung function at V1. Most of the participants without any obstructive pattern (74%) or with mild obstruction (64%) at V1 showed a faster absolute FEV1 decline, however PRISm showed faster relative decline than the other groups.
Conclusion: This study showed improved symptoms and quality of life with variable lung function trajectories among individuals with asthma who start regular treatment after decades of delay. Additionally, exacerbation during the first year was a strong predictor of absolute FEV1 decline and future exacerbations, while time without treatment was a predictor of relative reduction of FEV1.
{"title":"Exacerbation during the first year of treatment affects lung function in subjects with asthma - a 10-year follow-up.","authors":"Pca Almeida, Ev Ponte, R Stelmach, Tw Harrison, N Scichilone, A Souza-Machado, Aa Cruz","doi":"10.1080/02770903.2025.2451690","DOIUrl":"10.1080/02770903.2025.2451690","url":null,"abstract":"<p><strong>Background: </strong>Inhaled corticosteroids (ICS) are the preferred treatment for asthma. They improve symptoms and reduce exacerbations and deaths, but their long-term impact on lung function loss remains unclear, especially after delayed treatment. We aimed to characterize the lung function trajectories in subjects with previously untreated severe asthma. The secondary aim was to identify predictors of FEV<sub>1</sub> decline, and future exacerbations.</p><p><strong>Methods: </strong>This is a <i>post-hoc</i> analysis that followed 184 subjects with asthma for 10 years after a delayed start of regular maintenance ICS treatment. Absolute lung function variation was calculated using two different baselines: (i) FEV<sub>1</sub> after one year of regular treatment (V<sub>1</sub>) and (ii) best FEV<sub>1</sub> observed any time before the final visit.</p><p><strong>Results: </strong>Most individuals were female (84%) over 50 years old and had early-onset asthma with a median of 30 years without regular ICS treatment. Ninety-nine (54%) had an FEV1 decline above 25ml/year, using strategy (i). Those subjects were younger, had shorter duration of asthma, and had better lung function at V<sub>1</sub>. Most of the participants without any obstructive pattern (74%) or with mild obstruction (64%) at V<sub>1</sub> showed a faster absolute FEV<sub>1</sub> decline, however PRISm showed faster relative decline than the other groups.</p><p><strong>Conclusion: </strong>This study showed improved symptoms and quality of life with variable lung function trajectories among individuals with asthma who start regular treatment after decades of delay. Additionally, exacerbation during the first year was a strong predictor of absolute FEV<sub>1</sub> decline and future exacerbations, while time without treatment was a predictor of relative reduction of FEV<sub>1</sub>.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-06DOI: 10.1080/02770903.2025.2460549
Simona Luzzi, Tommaso Pianigiani, Akter Dilroba, Martina Meocci, Elisa Salvadori, Benedetta Picchi, Vittoria Ventura, Sara Croce, Laura Bergantini, Miriana D'Alessandro, Elena Bargagli, Paolo Cameli
Objective: Chest computed tomography (CT) is usually performed in patients with severe asthma (SA) to exclude concomitant conditions related to poor clinical control. Despite the growing evidence regarding the utility of CT in the characterization of morphological abnormalities and airway remodeling, its role in SA assessment is still largely unexplored. The aim of our systematic review was to evaluate published data investigating the role of chest CT in patients with SA.
Data sources: The systematic search was conducted on the Medline database through the Pubmed search engine.
Study selections: A total of 53 studies has been included.
Results: Quantitative CT (qCT) parameters generally differ between SA patients compared to mild to moderate asthmatic patients or healthy controls and are related to functional decline. CT parameters allow to identify image-based clusters reflecting remodeling patterns and/or air trapping features. The detection of mucus plugs is more frequent in severe eosinophilic asthma, and it is related to marked airway obstruction and ventilation defects. Benralizumab treatment appears to reduce or vanish mucus plugging. Most studies regarding CT and bronchial thermoplasty (BT) detect the usefulness of this investigation in predicting treatment response. Lastly, conflicting results surround the relation between chest CT and SA assessment in children due to also the scarcity of studies focusing on pediatric population.
Conclusions: The role of CT scans in SA is still debated. Most studies focus on the identification of CT-derived disease clusters while studies primarily evaluating the predicting role of CT scan to different biologics are lacking and could represent an interesting research area.
{"title":"Computed tomography in severe asthma assessment: a systematic review.","authors":"Simona Luzzi, Tommaso Pianigiani, Akter Dilroba, Martina Meocci, Elisa Salvadori, Benedetta Picchi, Vittoria Ventura, Sara Croce, Laura Bergantini, Miriana D'Alessandro, Elena Bargagli, Paolo Cameli","doi":"10.1080/02770903.2025.2460549","DOIUrl":"10.1080/02770903.2025.2460549","url":null,"abstract":"<p><strong>Objective: </strong>Chest computed tomography (CT) is usually performed in patients with severe asthma (SA) to exclude concomitant conditions related to poor clinical control. Despite the growing evidence regarding the utility of CT in the characterization of morphological abnormalities and airway remodeling, its role in SA assessment is still largely unexplored. The aim of our systematic review was to evaluate published data investigating the role of chest CT in patients with SA.</p><p><strong>Data sources: </strong>The systematic search was conducted on the Medline database through the Pubmed search engine.</p><p><strong>Study selections: </strong>A total of 53 studies has been included.</p><p><strong>Results: </strong>Quantitative CT (qCT) parameters generally differ between SA patients compared to mild to moderate asthmatic patients or healthy controls and are related to functional decline. CT parameters allow to identify image-based clusters reflecting remodeling patterns and/or air trapping features. The detection of mucus plugs is more frequent in severe eosinophilic asthma, and it is related to marked airway obstruction and ventilation defects. Benralizumab treatment appears to reduce or vanish mucus plugging. Most studies regarding CT and bronchial thermoplasty (BT) detect the usefulness of this investigation in predicting treatment response. Lastly, conflicting results surround the relation between chest CT and SA assessment in children due to also the scarcity of studies focusing on pediatric population.</p><p><strong>Conclusions: </strong>The role of CT scans in SA is still debated. Most studies focus on the identification of CT-derived disease clusters while studies primarily evaluating the predicting role of CT scan to different biologics are lacking and could represent an interesting research area.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-05DOI: 10.1080/02770903.2025.2458516
Olusegun Owotomo, Kristin A Riekert, Cynthia S Rand, Michelle N Eakin
Objective: Caregivers of children with asthma can become overwhelmed by the burden of care provision. Guided by the socioecological framework, we examined individual and system-level factors associated with caregiver health-related quality of life (HRQoL) among preschool children (aged two to six years) enrolled in a multilevel home- and school-based asthma educational intervention in Baltimore, Maryland.
Methods: The primary outcome was caregiver HRQoL measured at baseline and six months. Independent variables were baseline individual-level factors (caregiver's health literacy, self-efficacy to manage asthma, and depressive symptoms) and system-level factors (barriers to asthma care measured in five subdomains-pragmatics, health knowledge and beliefs, expectations, skills, and marginalization-and neighborhood social cohesion). Multiple regression models were used to assess the association between baseline individual and system-level factors and caregiver HRQoL at baseline and six-month follow-up adjusting for the child's asthma control, caregiver's age, household income, and study arm assignment/intervention.
Results: 398 caregivers completed the baseline survey and 328 (82%) completed the six-month follow-up survey. In the adjusted multiple regression model, lower caregiver's health literacy and higher barriers to asthma care related to pragmatics were significantly associated with lower caregiver HRQoL at baseline (b = 0.38, 95% CI, 0.15-0.61, p = .002; and b = 0.01, 95% CI, 0.004-0.02, p < .001, respectively). The results were similar at the six-month follow-up.
Conclusion: Caregiver health literacy and barriers to asthma care related to pragmatics and skills were found to be important determinants of asthma caregiver HRQoL. Addressing these factors may improve the quality of life among caregivers of preschool children with asthma.
{"title":"Individual and system-level determinants of caregivers' quality of life among inner-city preschool children with asthma.","authors":"Olusegun Owotomo, Kristin A Riekert, Cynthia S Rand, Michelle N Eakin","doi":"10.1080/02770903.2025.2458516","DOIUrl":"10.1080/02770903.2025.2458516","url":null,"abstract":"<p><strong>Objective: </strong>Caregivers of children with asthma can become overwhelmed by the burden of care provision. Guided by the socioecological framework, we examined individual and system-level factors associated with caregiver health-related quality of life (HRQoL) among preschool children (aged two to six years) enrolled in a multilevel home- and school-based asthma educational intervention in Baltimore, Maryland.</p><p><strong>Methods: </strong>The primary outcome was caregiver HRQoL measured at baseline and six months. Independent variables were baseline individual-level factors (caregiver's health literacy, self-efficacy to manage asthma, and depressive symptoms) and system-level factors (barriers to asthma care measured in five subdomains-pragmatics, health knowledge and beliefs, expectations, skills, and marginalization-and neighborhood social cohesion). Multiple regression models were used to assess the association between baseline individual and system-level factors and caregiver HRQoL at baseline and six-month follow-up adjusting for the child's asthma control, caregiver's age, household income, and study arm assignment/intervention.</p><p><strong>Results: </strong>398 caregivers completed the baseline survey and 328 (82%) completed the six-month follow-up survey. In the adjusted multiple regression model, lower caregiver's health literacy and higher barriers to asthma care related to pragmatics were significantly associated with lower caregiver HRQoL at baseline (<i>b</i> = 0.38, 95% CI, 0.15-0.61, <i>p</i> = .002; and <i>b</i> = 0.01, 95% CI, 0.004-0.02, <i>p</i> < .001, respectively). The results were similar at the six-month follow-up.</p><p><strong>Conclusion: </strong>Caregiver health literacy and barriers to asthma care related to pragmatics and skills were found to be important determinants of asthma caregiver HRQoL. Addressing these factors may improve the quality of life among caregivers of preschool children with asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-9"},"PeriodicalIF":1.7,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Persistent cough bothers many patients with asthma because it worsens their quality of life; therefore, it must be remedied immediately. The efficacy of triple therapy as a first-line treatment for cough remains unclear. To evaluate the effectiveness and safety of the triple therapy against persistent cough, the clinical effect of regular treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or placebo in adult patients with asthma was investigated.
Methods: This randomized, double-blind, placebo-controlled, parallel-group multicenter trial recruited asthma patients with persistent cough from hospitals and primary care clinics between June 2022 and December 2023. Participants were randomly given FF/UMEC/VI 200/62.5/25 µg or placebo for 6 wk. The primary endpoint was the average change in the cough symptom score from baseline to week 6. Secondary outcomes were effectiveness on cough-related disease burdens (asthma control questionnaire [ACQ]-5, Leicester cough questionnaire [LCQ] and nighttime awakening). Furthermore, lung function and adverse events were evaluated.
Results: The decrease from baseline in the cough symptom score at week 6 was significantly greater in the FF/UMEC/VI group than in the placebo group (p = 0.006). The ACQ-5 scores showed a greater decrease in the FF/UMEC/VI group than in the placebo group. The change from baseline in morning and evening FEV1 increased in the FF/UMEC/VI group as with the results of peak expiratory flow. No significant adverse events associated with FF/UMEC/VI were noted.
Conclusions: In asthma patients with persistent cough, FF/UMEC/VI showed an early response and a significant effect on cough and lung function for 6 wk of treatment.
This study is registered with jRCTs031210412.
{"title":"The efficacy and safety of Fluticasone Furoate/Umeclidinium/vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma, a randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study.","authors":"Etsuko Tagaya, Jun Shinada, Hiroyuki Nagase, Junko Terada-Hirashima, Masayuki Hojo, Naruhiko Sugihara, Osamitsu Yagi, Mayoko Tsuji, Tomohiro Akaba, Katsunori Masaki, Koichi Fukunaga, Hiroyuki Ohbayashi, Kaoru Chiba, Soichiro Hozawa, Ryo Atsuta, Yasuhiro Aoki, Hisato Hiranuma, Yasuhiro Gon, Akihiko Tanaka","doi":"10.1080/02770903.2025.2455416","DOIUrl":"10.1080/02770903.2025.2455416","url":null,"abstract":"<p><strong>Background: </strong>Persistent cough bothers many patients with asthma because it worsens their quality of life; therefore, it must be remedied immediately. The efficacy of triple therapy as a first-line treatment for cough remains unclear. To evaluate the effectiveness and safety of the triple therapy against persistent cough, the clinical effect of regular treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or placebo in adult patients with asthma was investigated.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled, parallel-group multicenter trial recruited asthma patients with persistent cough from hospitals and primary care clinics between June 2022 and December 2023. Participants were randomly given FF/UMEC/VI 200/62.5/25 µg or placebo for 6 wk. The primary endpoint was the average change in the cough symptom score from baseline to week 6. Secondary outcomes were effectiveness on cough-related disease burdens (asthma control questionnaire [ACQ]-5, Leicester cough questionnaire [LCQ] and nighttime awakening). Furthermore, lung function and adverse events were evaluated.</p><p><strong>Results: </strong>The decrease from baseline in the cough symptom score at week 6 was significantly greater in the FF/UMEC/VI group than in the placebo group (<i>p</i> = 0.006). The ACQ-5 scores showed a greater decrease in the FF/UMEC/VI group than in the placebo group. The change from baseline in morning and evening FEV<sub>1</sub> increased in the FF/UMEC/VI group as with the results of peak expiratory flow. No significant adverse events associated with FF/UMEC/VI were noted.</p><p><strong>Conclusions: </strong>In asthma patients with persistent cough, FF/UMEC/VI showed an early response and a significant effect on cough and lung function for 6 wk of treatment.</p><p><p>This study is registered with jRCTs031210412.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-11"},"PeriodicalIF":1.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2024-08-30DOI: 10.1080/02770903.2024.2394152
Gema Requena, Robert Wood, Risako Ito, Rosie Wild, Chifuku Mita, Poppy Payne, Isao Mukai, Catherine M Castillo, Steven Gelwicks, Rad Siddiqui, Stephen G Noorduyn, Toru Oga
Objective: In Japan, the optimal initiation timing and efficacy of single-inhaler triple therapy (SITT) in asthma management remain unexplored. This study investigated SITT initiation timing following an asthma exacerbation, and examined patient demographics and clinical characteristics.
Methods: Observational, retrospective cohort study in patients with asthma aged ≥15 years who initiated SITT following their earliest observed asthma exacerbation (February-November 2021), using data from Japanese health insurance claims databases (JMDC and Medical Data Vision [MDV]). The study period ended May 2022 for JMDC and September 2022 for MDV. Descriptive analyses were performed independently by database. Variables evaluated included timing of SITT initiation post exacerbation (prompt, delayed and late, ≤30, 31-180 and >180 days post index, respectively), patient demographics, clinical characteristics, and pre-index treatment.
Results: Of patients in the JMDC and MDV databases, most initiated SITT promptly after an asthma exacerbation, 60.8% (n = 951/1565) and 44.4% (n = 241/543), respectively. Delayed initiation occurred in 22.6% (n = 354/1565) and 26.3% (n = 143/543) of patients, and late initiation occurred in 16.6% (n = 260/1565) and 29.3% (n = 159/543), respectively. Most patients were indexed on a moderate asthma-related exacerbation, 97.1% (n = 1519/1565) and 68.7% (n = 373/543), respectively.
Conclusion: Most patients with asthma initiated SITT promptly following a moderate exacerbation, with delayed and late initiation more common among patients with complex clinical profiles. The findings underscore the necessity for future research to examine the interaction between patient characteristics, clinical outcomes, and the timing of SITT initiation to optimize treatment strategies, as clinical practice may vary by exacerbation severity.
目的:在日本,单次吸入三联疗法(SITT)在哮喘治疗中的最佳启动时机和疗效仍有待探索。本研究调查了哮喘加重后启动 SITT 的时机,并考察了患者的人口统计学和临床特征:观察性、回顾性队列研究:利用日本健康保险索赔数据库(JMDC 和 Medical Data Vision [MDV])中的数据,对年龄≥15 岁的哮喘患者进行观察,这些患者在最早观察到的哮喘加重后(2021 年 2 月至 11 月)开始使用 SITT。JMDC 的研究时间截至 2022 年 5 月,MDV 的研究时间截至 2022 年 9 月。描述性分析按数据库独立进行。评估变量包括病情加重后启动 SITT 的时间(及时、延迟和晚期,分别为指数后≤30 天、31-180 天和 >180 天)、患者人口统计学特征、临床特征和指数前治疗:在JMDC和MDV数据库中,大多数患者在哮喘加重后立即开始SITT治疗,分别为60.8%(n=951/1565)和44.4%(n=241/543)。延迟启动的患者分别占 22.6%(n = 354/1565)和 26.3%(n = 143/543),逾期启动的患者分别占 16.6%(n = 260/1565)和 29.3%(n = 159/543)。结论:大多数哮喘患者都是在哮喘相关症状中度加重时接受治疗的,分别为 97.1%(n = 1519/1565)和 68.7%(n = 373/543):结论:大多数哮喘患者在中度哮喘加重后都会立即启动 SITT,而在临床情况复杂的患者中,延迟启动 SITT 的情况更为常见。这些发现强调了未来研究的必要性,即研究患者特征、临床结果和启动 SITT 的时机之间的相互作用,以优化治疗策略,因为临床实践可能会因病情加重的严重程度而有所不同。
{"title":"Evaluating the timing of triple therapy initiation for the treatment of asthma in Japan: prompt versus delayed.","authors":"Gema Requena, Robert Wood, Risako Ito, Rosie Wild, Chifuku Mita, Poppy Payne, Isao Mukai, Catherine M Castillo, Steven Gelwicks, Rad Siddiqui, Stephen G Noorduyn, Toru Oga","doi":"10.1080/02770903.2024.2394152","DOIUrl":"10.1080/02770903.2024.2394152","url":null,"abstract":"<p><strong>Objective: </strong>In Japan, the optimal initiation timing and efficacy of single-inhaler triple therapy (SITT) in asthma management remain unexplored. This study investigated SITT initiation timing following an asthma exacerbation, and examined patient demographics and clinical characteristics.</p><p><strong>Methods: </strong>Observational, retrospective cohort study in patients with asthma aged ≥15 years who initiated SITT following their earliest observed asthma exacerbation (February-November 2021), using data from Japanese health insurance claims databases (JMDC and Medical Data Vision [MDV]). The study period ended May 2022 for JMDC and September 2022 for MDV. Descriptive analyses were performed independently by database. Variables evaluated included timing of SITT initiation post exacerbation (prompt, delayed and late, ≤30, 31-180 and >180 days post index, respectively), patient demographics, clinical characteristics, and pre-index treatment.</p><p><strong>Results: </strong>Of patients in the JMDC and MDV databases, most initiated SITT promptly after an asthma exacerbation, 60.8% (<i>n</i> = 951/1565) and 44.4% (<i>n</i> = 241/543), respectively. Delayed initiation occurred in 22.6% (<i>n</i> = 354/1565) and 26.3% (<i>n</i> = 143/543) of patients, and late initiation occurred in 16.6% (<i>n</i> = 260/1565) and 29.3% (<i>n</i> = 159/543), respectively. Most patients were indexed on a moderate asthma-related exacerbation, 97.1% (<i>n</i> = 1519/1565) and 68.7% (<i>n</i> = 373/543), respectively.</p><p><strong>Conclusion: </strong>Most patients with asthma initiated SITT promptly following a moderate exacerbation, with delayed and late initiation more common among patients with complex clinical profiles. The findings underscore the necessity for future research to examine the interaction between patient characteristics, clinical outcomes, and the timing of SITT initiation to optimize treatment strategies, as clinical practice may vary by exacerbation severity.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"216-225"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2024-09-09DOI: 10.1080/02770903.2024.2400601
Ourania S Kotsiou, Georgios I Barkas, Katerina Kokkinidou, Dimitra I Siachpazidou, Konstantinos I Gourgoulianis, Zoe Daniil
Background: Asthma, a chronic inflammatory condition affecting the airways, significantly impacts both respiratory function and quality of life. Recent studies have highlighted the psychological dimensions of chronic diseases like asthma. Despite growing evidence linking asthma with various psychopathological conditions, comprehensive data remains scarce.
Aim: This study aims to explore the psychopathological status of asthma patients and identify demographic and clinical factors associated with higher levels of psychopathological symptoms.
Methods: Data were collected from 42 asthma patients attending the Asthma Outpatient Clinic at the University of Thessaly, Greece. Participants completed a detailed questionnaire on demographics and clinical parameters, along with the Symptoms Checklist-90 (SCL-90) to assess psychological symptoms.
Results: The sample included patients with varying asthma severity: 38% with severe asthma and 62% with mild-moderate asthma, with a mean age of 60.8 ± 15.6 years. Results indicated that 23.8% exhibited somatization symptoms, 23.8% showed compulsive behaviors, 33.8% reported interpersonal sensitivity, and 38.1% experienced depression and 38.1% aggressiveness. Additionally, 45.2% struggled with fearful anxiety, 4.8% showed paranoid ideation, and 11.9% had traits of psychoticism. Women had significantly higher psychopathology scores than men. Factors such as longer disease duration, uncontrolled asthma, severe asthma, and comorbid conditions like atopy and gastroesophageal reflux disease (GERD) were linked to higher psychopathological scores.
Conclusions: The study found a high prevalence of psychopathological symptoms among asthma patients. Female gender, prolonged asthma duration, persistent symptoms, comorbid diseases (GERD, atopy) and greater disease severity were significantly associated with higher psychopathology, underscoring the need for integrated mental health care in asthma management.
{"title":"Psychopathology in asthma patients: analysis of demographic and clinical associations.","authors":"Ourania S Kotsiou, Georgios I Barkas, Katerina Kokkinidou, Dimitra I Siachpazidou, Konstantinos I Gourgoulianis, Zoe Daniil","doi":"10.1080/02770903.2024.2400601","DOIUrl":"10.1080/02770903.2024.2400601","url":null,"abstract":"<p><strong>Background: </strong>Asthma, a chronic inflammatory condition affecting the airways, significantly impacts both respiratory function and quality of life. Recent studies have highlighted the psychological dimensions of chronic diseases like asthma. Despite growing evidence linking asthma with various psychopathological conditions, comprehensive data remains scarce.</p><p><strong>Aim: </strong>This study aims to explore the psychopathological status of asthma patients and identify demographic and clinical factors associated with higher levels of psychopathological symptoms.</p><p><strong>Methods: </strong>Data were collected from 42 asthma patients attending the Asthma Outpatient Clinic at the University of Thessaly, Greece. Participants completed a detailed questionnaire on demographics and clinical parameters, along with the Symptoms Checklist-90 (SCL-90) to assess psychological symptoms.</p><p><strong>Results: </strong>The sample included patients with varying asthma severity: 38% with severe asthma and 62% with mild-moderate asthma, with a mean age of 60.8 ± 15.6 years. Results indicated that 23.8% exhibited somatization symptoms, 23.8% showed compulsive behaviors, 33.8% reported interpersonal sensitivity, and 38.1% experienced depression and 38.1% aggressiveness. Additionally, 45.2% struggled with fearful anxiety, 4.8% showed paranoid ideation, and 11.9% had traits of psychoticism. Women had significantly higher psychopathology scores than men. Factors such as longer disease duration, uncontrolled asthma, severe asthma, and comorbid conditions like atopy and gastroesophageal reflux disease (GERD) were linked to higher psychopathological scores.</p><p><strong>Conclusions: </strong>The study found a high prevalence of psychopathological symptoms among asthma patients. Female gender, prolonged asthma duration, persistent symptoms, comorbid diseases (GERD, atopy) and greater disease severity were significantly associated with higher psychopathology, underscoring the need for integrated mental health care in asthma management.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"290-302"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The association of cardiovascular health (CVH) with asthma risk in U.S. adults remains unclear. This study aimed to explore the association of Life's Essential 8 (LE8), a measurement of CVH, with asthma and investigate the potential mediating effect of inflammation and oxidative stress.
Methods: The data was obtained from the National Health and Nutrition Examination Survey (NHANES) in 2005-2018. LE8 score (range 0 ∼ 100) was measured and categorized as low (<50), moderate (50 ∼ <80), and high (≥80) CVH. Survey-weighted logistic regression and restricted cubic spline model were employed to explore the association between LE8 score and asthma. Mediation analyses were conducted to identify the mediating effects of inflammation and oxidative stress biomarkers.
Results: This study included 10,932 participants aged ≥ 20 years, among whom 890 (8.14%) reported prevalent asthma. After adjusting for all covariates, the odd ratios (OR) for asthma were 0.67 (95% confidence interval (CI): 0.48, 0.94) in the moderate CVH group and 0.52 (95% CI: 0.34, 0.79) in the high CVH group compared with the low CVH group, respectively. The OR for asthma was 0.85 (95% CI: 0.78, 0.93) for every 10 score increase in LE8 score, and linear dose-response relationship was observed (p = 0.0642). Mediation analyses showed that inflammation and oxidative stress mediated 15.97% and 11.50% of the association between LE8 score and asthma, respectively (all p < 0.05).
Conclusions: LE8 score was negatively associated with asthma, and inflammation and oxidative stress partially mediated this association. It is recommended that maintaining optimal CVH may prevent asthma.
{"title":"Association of life's essential 8 and asthma: mediating effect of inflammation and oxidative stress.","authors":"Guibin Shen, Yongli Yang, Nana Wang, Shangxin Shi, Yongyue Chen, Ying Qiao, Xiaocan Jia, Xuezhong Shi","doi":"10.1080/02770903.2024.2400613","DOIUrl":"10.1080/02770903.2024.2400613","url":null,"abstract":"<p><strong>Background: </strong>The association of cardiovascular health (CVH) with asthma risk in U.S. adults remains unclear. This study aimed to explore the association of Life's Essential 8 (LE8), a measurement of CVH, with asthma and investigate the potential mediating effect of inflammation and oxidative stress.</p><p><strong>Methods: </strong>The data was obtained from the National Health and Nutrition Examination Survey (NHANES) in 2005-2018. LE8 score (range 0 ∼ 100) was measured and categorized as low (<50), moderate (50 ∼ <80), and high (≥80) CVH. Survey-weighted logistic regression and restricted cubic spline model were employed to explore the association between LE8 score and asthma. Mediation analyses were conducted to identify the mediating effects of inflammation and oxidative stress biomarkers.</p><p><strong>Results: </strong>This study included 10,932 participants aged ≥ 20 years, among whom 890 (8.14%) reported prevalent asthma. After adjusting for all covariates, the odd ratios (OR) for asthma were 0.67 (95% confidence interval (CI): 0.48, 0.94) in the moderate CVH group and 0.52 (95% CI: 0.34, 0.79) in the high CVH group compared with the low CVH group, respectively. The OR for asthma was 0.85 (95% CI: 0.78, 0.93) for every 10 score increase in LE8 score, and linear dose-response relationship was observed (<i>p =</i> 0.0642). Mediation analyses showed that inflammation and oxidative stress mediated 15.97% and 11.50% of the association between LE8 score and asthma, respectively (all <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>LE8 score was negatively associated with asthma, and inflammation and oxidative stress partially mediated this association. It is recommended that maintaining optimal CVH may prevent asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"328-335"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2024-09-11DOI: 10.1080/02770903.2024.2400285
Megan D McDonald, Danyel Dantzler, Michelle Nichols, Sarah Miller, Erin Dawley, Mason Walgrave, Andrea Denise Boan, Ronald J Teufel
Objective: Mobile health (mHealth), defined as the use of mobile phones or applications in healthcare, has been developed to enhance asthma care; yet implementation is inconsistent, and few studies have focused on provider perspectives on use in daily practice. The purpose of this study was to explore primary care pediatric provider perspectives regarding mHealth use in clinical practice for children with asthma.
Methods: A qualitative, descriptive approach was utilized to perform semi-structured interviews on asthma mHealth use with providers caring for children with asthma. Interview transcripts were coded by two independent investigators and any differences were reconciled. Interviews continued until thematic saturation was achieved.
Results and conclusions: Seventeen pediatric providers were recruited and interviewed. Three themes identified included implementation benefits, implementation barriers, and reporting desires, with 11 subthemes. Many subthemes were consistent across providers (e.g. self-management benefits and electronic medical record integration), while others such as provider clinical burden and approach to integrating mHealth data reports into daily workflow demonstrated variability. Provider perspectives highlight the potential of mHealth applications in asthma self-management while offering challenges related to clinical burden and suggestions for reporting and workflow integration. These results provide valuable perspectives on mHealth use and reporting to ensure provider efficiency and technology-enhanced asthma care. This study investigates pediatric provider perspectives on asthma mobile health use and reporting in daily practice, a topic that has not sufficiently been explored within the literature. Results can guide best practices, encourage more consistent use, and maximize the benefits of asthma mHealth tools by providers.
{"title":"Reporting of asthma mobile health data for clinical practice: a qualitative study of pediatric provider perspectives.","authors":"Megan D McDonald, Danyel Dantzler, Michelle Nichols, Sarah Miller, Erin Dawley, Mason Walgrave, Andrea Denise Boan, Ronald J Teufel","doi":"10.1080/02770903.2024.2400285","DOIUrl":"10.1080/02770903.2024.2400285","url":null,"abstract":"<p><strong>Objective: </strong>Mobile health (mHealth), defined as the use of mobile phones or applications in healthcare, has been developed to enhance asthma care; yet implementation is inconsistent, and few studies have focused on provider perspectives on use in daily practice. The purpose of this study was to explore primary care pediatric provider perspectives regarding mHealth use in clinical practice for children with asthma.</p><p><strong>Methods: </strong>A qualitative, descriptive approach was utilized to perform semi-structured interviews on asthma mHealth use with providers caring for children with asthma. Interview transcripts were coded by two independent investigators and any differences were reconciled. Interviews continued until thematic saturation was achieved.</p><p><strong>Results and conclusions: </strong>Seventeen pediatric providers were recruited and interviewed. Three themes identified included implementation benefits, implementation barriers, and reporting desires, with 11 subthemes. Many subthemes were consistent across providers (e.g. self-management benefits and electronic medical record integration), while others such as provider clinical burden and approach to integrating mHealth data reports into daily workflow demonstrated variability. Provider perspectives highlight the potential of mHealth applications in asthma self-management while offering challenges related to clinical burden and suggestions for reporting and workflow integration. These results provide valuable perspectives on mHealth use and reporting to ensure provider efficiency and technology-enhanced asthma care. This study investigates pediatric provider perspectives on asthma mobile health use and reporting in daily practice, a topic that has not sufficiently been explored within the literature. Results can guide best practices, encourage more consistent use, and maximize the benefits of asthma mHealth tools by providers.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"261-270"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01Epub Date: 2024-09-21DOI: 10.1080/02770903.2024.2394145
Florence Joulain, Kinga Borsos, Wei-Han Cheng, Clara Engroba-Teijeiro, Zhixiao Wang
{"title":"Letter to the editor regarding \"Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain\".","authors":"Florence Joulain, Kinga Borsos, Wei-Han Cheng, Clara Engroba-Teijeiro, Zhixiao Wang","doi":"10.1080/02770903.2024.2394145","DOIUrl":"10.1080/02770903.2024.2394145","url":null,"abstract":"","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"362-364"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}